key: cord-0974322-oilyr6qm
authors: Bessis, D.
title: Impaired type I interferon response in SARS‐CoV‐2 infection: looking through the cutaneous window
date: 2020-11-29
journal: Br J Dermatol
DOI: 10.1111/bjd.19596
sha: 63ae1e75b4a4de6595b92d47cd6dc326537e14f6
doc_id: 974322
cord_uid: oilyr6qm

nan

Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, strong evidence has accumulated for the key role of an inappropriate, insufficient, overactive and/or delayed type I (mainly alpha and beta) interferon response during SARS-CoV-2 infection. Most studies have concerned critically ill patients with COVID-19 and the results have been discrepant and even contradictory. This likely reflects differences in the criteria of the studies, such as timing of sampling, nature of the affected organs, severity of the disease and presence of comorbidities. [1] [2] [3] [4] To date, about 1500 cases of chilblain-like (perniosis-like) skin lesions have been reported during SARS-CoV-2 infection (initially referred to as 'COVID toes'), with the following data highlighted: elective occurrence in young adults, milder disease spontaneously resolving, and low rate of positivity to SARS-CoV-2 nasopharyngeal polymerase chain reaction (PCR) or blood serology. More recently, a causative role of SARS-CoV-2 in this outbreak of chilblain-like lesions (since named COVID-19 chilblains) was confirmed by the immunohistochemical and ultrastructural identification of direct viral infection in the endothelial cells of the upper dermal vessels and the epithelial cells of eccrine glands. 5 The clinical and histopathological similarities of COVID-19 chilblains to the acral cutaneous lesions observed in genetic interferonopathies, notably familial chilblain lupus and STING-associated vasculopathy with onset in infancy (SAVI), 6 suggest a pivotal pathogenic role of upregulation of type I interferon response in causing these skin lesions. These data have prompted the hypothesis of a pathophysiological mechanism of COVID-19 chilblains that can be summarized as follows: high production of type I interferon at the onset of viral infectionperhaps a hallmark in children, young adults and predisposed patientsis associated with the early and rapid inhibition of the replication and clearance of the virus, accounting for the mild disease course, the usually negative PCR test positivity and the negativity of serologies. 7, 8 In this issue of the BJD, Magro and colleagues compared the histopathological and immunohistochemical staining of SARS-CoV-2 protein and RNA and the cytokine features in a short series of idiopathic perniosis, COVID-19 chilblains and retiform purpura of severe or critically ill patients with COVID. 9 They thus confirmed the marked separation in the histological pattern of the two cutaneous manifestations of COVID-19. COVID-19 chilblains comprise a highly lymphocytic inflammatory process with a type I interferon-enriched microenvironment, as evidenced by extensive epidermal and dermal expression of MxA and rich presence of plasmacytoid dendritic cells, and minimal vascular injury in COVID-19 chilblains. On the other hand, COVID retiform purpura reveals a pauci-inflammatory thrombotic complement-driven microvascular injury syndrome. In the latter case, microscopic and immunohistological findings were strikingly similar to the septal capillary injury observed in pulmonary autopsy samples of patients who died of acute respiratory distress syndrome, suggesting a common pathophysiological mechanism. 10 The study also highlights the quantitative and anatomical variations of viral protein expression: mild and mostly in inflammatory cells in COVID-19 chilblains, and extensive and endothelial in COVID retiform purpura.

In summary, Magro and colleagues provide further indirect confirmation of the key role of an impaired type I interferon response in SARS-CoV-2 infection during COVID-19 chilblains and retiform purpura by skin immunophenotyping. Nevertheless, additional longitudinal studies of type I interferon signatures in peripheral white blood cells and lesional skin are needed to provide direct evidence of this concept. 

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Imbalanced host response to SARS-CoV-2 drives development of COVID-19

Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling

Type I IFN immunoprofiling in COVID-19 patients

SARS-CoV-2 endothelial infection causes COVID-19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases

Stimulator of interferon genesassociated vasculopathy with onset in infancy: a mimic of childhood granulomatosis with polyangiitis

When interferon tiptoes through COVID-19: pernio-like lesions and their prognostic implications during SARS-CoV-2 infection

Negative tests for SARS-CoV-2 infection do not rule out its responsibility for chilblains

The differing pathophysiologies that underlie COVID-19-associated perniosis and thrombotic retiform purpura: a case series

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases